Look At Analyst Expectations For A Better Read On Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP)
Currently, there are 227.17M common shares owned by the public and among those 156.52M shares have been available to trade. The company’s stock has a 5-day price change of 10.06% and 211.67% over the past three months. ADAP shares are trading 120.68% year to date (YTD), with the 12-month market performance up to 45.83% higher. […]
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) – Suitable For Long Term Buy?
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling […]